Experts In The News
You had questions, and we’ve got the answers!
Renee Summerour sits down with Dr. Brian Labus, Epidemiologist with the 51³Ô¹ÏºÚÁÏ School of Public Health and the governor’s medical advisory team, and Rj Health reporter Mary Hynes to answer viewer questions regarding the Coronavirus spread in Nevada.
Crowds at Las Vegas-area markets have thinned, and items like eggs, chicken and even toilet paper are again readily available as the COVID-19 panic shopping has ceased. But cruise down the cleaning aisles and you’ll still find shelves mostly empty of bleach and hand sanitizers.
A study that links air conditioning with a coronavirus outbreak at a restaurant in China is not what Southern Nevadans want to hear about on Wednesday, which is predicted to be the Las Vegas Valley’s first triple-digit day of 2020.
A significant change at the top of Nevada's employment department was announced Tuesday with the director stepping down.
Today, it's the coronavirus that gives us a sense of uncertainty about the future. For several decades, that feeling came from the very real possibility of nuclear war.
As the COVID-19 pandemic rages on, the focus unsurprisingly has been on the exigent and obvious. No matter which industry you’re in, this pandemic threatens not only your life but your financial health. Though much has been written about industries in peril, far less has been written about industries—like law—that are poised to enjoy a Renaissance.
As we continue to learn more about COVID-19, we are also discovering the best ways to protect ourselves and others. The Center for Disease Control (CDC) is currently recommending wearing masks in order to slow the spread of the coronavirus. Since you can spread it without having symptoms, it is important to wear a non-medical grade mask (save the N-95s for our medical workers!) when in public places, even when adhering to social distancing practices.
An experimental drug could help caregivers as well as patients, as it substantially improved agitation in Alzheimer's patients in a late-stage clinical trial. The announcement boosted the shares of the maker of the treatment, Axsome Therapeutics (AXSM), nearly 25% to more than $95.
